Skip to main content
CLRB
NASDAQ Life Sciences

Final Prospectus Filed for Resale of 51.9M Shares, Potential $108.2M from Warrants

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.888
Mkt Cap
$23.736M
52W Low
$2.43
52W High
$20.595
52W Position info
19% above low
Off High info
86% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

CLRB sits 19% above its 52-week low of $2.43 on light trading volume (0.2× avg).

Summary

Cellectar Biosciences filed the final prospectus for the resale of 51.9 million shares by selling stockholders, which could bring in $108.2 million from warrant exercises but also represents massive potential dilution.


Key Events · Financing and Capital Events · CLRB

  • Resale Registration Finalized

    Final prospectus filed for the resale of up to 51,998,413 shares of common stock by selling stockholders.

  • Origin of Shares

    These shares originate from a private placement and registered direct offering that closed on May 6, 2026, and associated warrants.

  • Potential Cash Inflow

    The company expects to receive $108.2 million if all associated warrants are exercised for cash.

  • Extreme Dilution

    The shares registered for resale represent approximately 887% of the company's currently outstanding common stock, indicating significant potential dilution.


Analysis · CLRB · Life Sciences

This filing finalizes the registration for the resale of over 51.9 million shares by selling stockholders, stemming from a recent private placement and registered direct offering. While the company will not receive proceeds from the resale itself, it stands to gain $108.2 million if all associated warrants are exercised for cash. This potential cash infusion is critical for the company, which has expressed substantial doubt about its ability to continue as a going concern. However, the registration of such a large volume of shares for resale, representing approximately 887% of the current outstanding shares, creates a significant market overhang and poses extreme dilution risk for existing shareholders.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CLRB was trading at $2.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.7M. The 52-week trading range was $2.43 to $20.59. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CLRB - Latest Insights

CLRB
Nov 10, 2026, 7:15 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.30
Real-time Price: $0.877 info
Change: -$0.423 (-33%) info
Market Cap: $8.804M info
CLRB
Nov 10, 2026, 6:55 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.28
Real-time Price: $0.877 info
Change: -$0.403 (-31%) info
Market Cap: $8.804M info
CLRB
Sep 29, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.80
Real-time Price: $0.877 info
Change: -$0.9225 (-51%) info
Market Cap: $8.804M info
CLRB
Aug 13, 2026, 7:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.60
Real-time Price: $0.877 info
Change: -$1.72 (-66%) info
Market Cap: $8.804M info
CLRB
Aug 13, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.60
Real-time Price: $0.877 info
Change: -$1.72 (-66%) info
Market Cap: $8.804M info